Eversept Partners, LP Portfolio
Auto-discovered 13F filer (Top-2000 by latest reported value).
SEC 13F CIK: 0001697013
What is a 13F filing? Who files one and when · What 13F filings can't tell you
Q2 2024 · 74 positions · Total reported value $1.46B · Top-10 concentration 61.2% · Updated 2026-10-18
Last updated: 2026-10-18 · Source: SEC EDGAR Form 13F-HR
Turnover: 66.4% · 29 new · 41 cut · 27 exited
Active Share (vs S&P 500): 97.5% · vs QQQ: 99.8% — share of the book that differs from index weights (higher = more active) · ranking
Est. Qtr Return (Q1 2026 → Q2 2026): +11.9% · vs SPY -2.9% · Prev Value $1.87B — last quarter positions weighted by this quarter price moves · ranking
In its Q2 2024 13F filing, Eversept Partners, LP disclosed 74 equity positions with a combined reported value of $1.46B. The filing implies a focused portfolio: its ten largest positions account for 61.2% of reported value. HoldingsHub classifies the profile as Mid / Focused / Health Tilt / High Turnover.
The largest disclosed positions as of Q2 2024 were QQQ ($136.83M), GSK ($133.52M), NTRA ($127.08M). By sector, the heaviest allocations are Health Care 79.6%, Industrials 4.1%. Versus the prior quarter, allocation shifted toward Health Care (+2.3pp) and away from Other (-2.0pp).
Versus the prior quarter, Eversept Partners, LP opened 29 new positions, trimmed 41 and fully exited 27, a turnover rate of 66.4% of positions. The portfolio's overlap with the prior quarter was 67% of names.
The largest new positions opened in Q2 2024 were INSM ($77.42M), XBI ($9.27M), ARQT ($7.79M).
Of the 27 positions fully exited versus the prior quarter, the largest were PFE ($30.58M), SWAV ($26.23M), THC ($18.46M).
Figures come from the fund's SEC Form 13F filing. 13F reports are filed within 45 days of quarter end and cover long positions of $100,000 or more; they exclude short positions and non-13F asset classes, so treat this page as a quarter-end snapshot rather than the fund's live book.
New Positions (Q2 2024)
- INSM INSMED INC · $77.42M
- XBI SPDR SERIES TRUST · $9.27M
- ARQT ARCUTIS BIOTHERAPEUTICS INC · $7.79M
- CYTK CYTOKINETICS INC · $6.87M
- EOLS EVOLUS INC · $6.23M
- OSCR OSCAR HEALTH INC · $4.92M
- CERE CEREVEL THERAPEUTICS HLDNG I · $4.50M
- MYGN MYRIAD GENETICS INC · $4.45M
Fully Exited (vs previous quarter)
- PFE PFIZER INC · prev qtr: $30.58M
- SWAV SHOCKWAVE MED INC · prev qtr: $26.23M
- THC TENET HEALTHCARE CORP · prev qtr: $18.46M · history
- TARO TARO PHARMACEUTICAL INDS LTD · prev qtr: $11.16M
- TSHA TAYSHA GENE THERAPIES INC · prev qtr: $6.67M
- WAT WATERS CORP · prev qtr: $4.69M
- CRBP CORBUS PHARMACEUTICALS · prev qtr: $3.49M
- KRYS KRYSTAL BIOTECH INC · prev qtr: $3.30M
Insider Transactions (Form 4)
Latest Eversept Partners, LP buys and sells reported on SEC Form 4 — filed within two business days when the fund's ownership in a stock crosses 10%.
No Form 4 filings for this fund yet — when its ownership in a stock crosses 10%, buys and sells are filed here within two business days.
Fund Profile
Eversept Partners, LP is an SEC-registered 13F filer based in New York, NY, United States. As of Q2 2026 it reported 119 US equity positions with a combined value of $1.91B. HoldingsHub carries 12 quarters of its filings (Q3 2023–Q2 2026).
Firm Snapshot
- Headquarters: NEW YORK, NY, United States
- SEC registration: 801-108771 (status: Approved), registered 2017-01-11
- Regulatory AUM (Form ADV): $2.65B as of 2026-03-31
- Client mix (by RAUM): pension and profit-sharing plans 99%, registered investment companies 1%
- Manages 3 private funds, of which 3 hedge funds
- Website: eversept.com
Portfolio Structure
- 119 positions · $1.91B reported value (Q2 2026)
- Top 10 holdings = 46.1% of reported value
- Largest position: UTHR (UNITED THERAPEUTICS CORP DEL) at 8.2%
- Average position size: $16.06M
Sector Tilt
- Health Care 88.2%
- Real Estate 5.6%
- Industrials 1.3%
- (classified holdings cover 96% of value)
Quarterly Activity
- Q2 2026: 29 new, 42 added, 41 reduced, 27 exited
- 7 positions unchanged
Generated from the firm's public SEC Form 13F and ADV filings. It states what the firm has reported — not an evaluation of its strategy, and not investment advice.
| # | Company | Shares | Value | Weight | Allocation | Change |
|---|---|---|---|---|---|---|
| 1 |
|
285.60K | $136.83M | 9.37% | Reduce | |
| 2 |
|
3.47M | $133.52M | 9.14% | Reduce | |
| 3 |
|
1.17M | $127.08M | 8.70% | Reduce | |
| 4 |
|
1.16M | $77.42M | 5.30% | New | |
| 5 |
|
4.72M | $76.71M | 5.25% | Reduce | |
| 6 |
|
235.35K | $74.97M | 5.13% | Reduce | |
| 7 |
|
3.61M | $74.19M | 5.08% | Add | |
| 8 |
|
2.04M | $73.92M | 5.06% | Add | |
| 9 |
|
533.01K | $71.33M | 4.88% | Add | |
| 10 |
|
451.58K | $47.35M | 3.24% | Reduce | |
| 11 |
|
135.48K | $43.53M | 2.98% | Add | |
| 12 |
|
543.04K | $38.91M | 2.66% | Reduce | |
| 13 |
|
413.53K | $35.65M | 2.44% | Reduce | |
| 14 |
|
8.04M | $27.01M | 1.85% | Add | |
| 15 |
|
194.29K | $24.49M | 1.68% | Add | |
| 16 |
|
633.01K | $23.43M | 1.60% | Reduce | |
| 17 |
|
456.88K | $21.77M | 1.49% | Add | |
| 18 |
|
146.96K | $20.98M | 1.44% | Add | |
| 19 |
|
21.23K | $19.22M | 1.32% | Add | |
| 20 |
|
505.84K | $17.53M | 1.20% | Add | |
| 21 |
|
30.80K | $16.76M | 1.15% | Add | |
| 22 |
|
34.59K | $14.88M | 1.02% | Reduce | |
| 23 |
|
38.02K | $14.21M | 0.97% | Add | |
| 24 |
|
1.33M | $14.13M | 0.97% | Add | |
| 25 |
|
767.66K | $14.01M | 0.96% | Add | |
| 26 |
|
2.26M | $11.78M | 0.81% | Reduce | |
| 27 |
|
1.55M | $10.56M | 0.72% | Add | |
| 28 |
|
40.85K | $10.21M | 0.70% | Hold | |
| 29 |
|
100.00K | $9.27M | 0.64% | New | |
| 30 |
|
1.09M | $8.97M | 0.61% | Add | |
| 31 |
|
14.66K | $7.94M | 0.54% | Add | |
| 32 |
|
837.85K | $7.79M | 0.53% | New | |
| 33 |
|
115.82K | $7.68M | 0.53% | Add | |
| 34 |
|
567.49K | $7.38M | 0.51% | Add | |
| 35 |
|
138.49K | $7.34M | 0.50% | Add | |
| 36 |
|
96.09K | $7.26M | 0.50% | Reduce | |
| 37 |
|
1.15M | $7.12M | 0.49% | Reduce | |
| 38 |
|
126.88K | $6.87M | 0.47% | New | |
| 39 |
|
329.89K | $6.34M | 0.43% | Reduce | |
| 40 |
|
574.46K | $6.23M | 0.43% | New | |
| 41 |
|
18.28K | $5.43M | 0.37% | Add | |
| 42 |
|
1.74M | $5.10M | 0.35% | Add | |
| 43 |
|
5.48M | $4.94M | 0.34% | Reduce | |
| 44 |
|
310.89K | $4.92M | 0.34% | New | |
| 45 |
|
110.01K | $4.50M | 0.31% | New | |
| 46 |
|
373.55K | $4.48M | 0.31% | Reduce | |
| 47 |
|
181.96K | $4.45M | 0.30% | New | |
| 48 |
|
1.33M | $4.33M | 0.30% | Reduce | |
| 49 |
|
4.99M | $4.33M | 0.30% | Reduce | |
| 50 |
|
1.11M | $4.26M | 0.29% | Reduce | |
FAQ
What did Eversept Partners, LP buy in 2024-Q2?
In its 2024-Q2 13F filing, Eversept Partners, LP reported 74 equity positions worth $1.46B in aggregate; its largest disclosed positions were QQQ ($136.83M), GSK ($133.52M), NTRA ($127.08M).
How large is Eversept Partners, LP's portfolio?
Eversept Partners, LP reported $1.46B of long equity holdings across 74 positions as of 2024-Q2. Top-10 holdings account for 61.2% of reported value.
What is Eversept Partners, LP's investment style?
HoldingsHub classifies the portfolio as Mid / Focused / Health Tilt / High Turnover, computed from size, concentration, sector tilt and turnover.
Where does this data come from?
All figures are computed from the fund's SEC Form 13F quarterly filing, which must be filed within 45 days of quarter end for long positions of $100,000 or more.